Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 12, 2020
Daily News
May 12, 2020
- Investigator Calls for Early Listing of Zolgensma in Japan
May 12, 2020
- Keytruda Keeps Top Spot in April Drug Ranking: Encise
May 12, 2020
- Govt Officials Urge Japan Pharma Companies to Be More Proactive in Coronavirus Vaccine Development
May 12, 2020
- Shionogi Suffers Lower Earnings as Xofluza Sales Dive 98.4% in FY2019
May 12, 2020
- Santen Snaps Up Exclusive Rights for US Biotech’s Eye Cell Therapy in Japan, Asia, Europe
May 12, 2020
- Daiichi Sankyo Chairman Nakayama to Step Aside as Adviser
May 12, 2020
- Japan COVID-19 Vaccine Trial Could Begin as Early as July: Abe
May 12, 2020
- Zolgensma to Get Japan’s Highest List Price 167 Million Yen, but Peak Sales Put at Just 4 Billion Yen
May 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…